List of works - Joachim Gullbo

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

scientific article

Aminopeptidase N (CD13) as a target for cancer chemotherapy

scientific article

Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan ⬇️

scientific article published on September 1, 2003

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.

scientific article published on December 2003

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

scientific article

Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

scientific article published in January 2010

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.

scientific article published on January 2004

Evaluation of toxicity and antitumor activity of cycloviolacin O2 in mice

scientific article published on January 2010

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

scientific article published on 9 October 2011

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

scientific article

Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram

scientific article

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

scientific article

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

scientific article published on 8 June 2017

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells

scientific article

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

scientific article

Novel activity of acriflavine against colorectal cancer tumor cells

scientific article

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

scientific article

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

scientific article

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

scientific article published in August 2006

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

scientific article published on 11 January 2013

Preclinical activity of melflufen (J1) in ovarian cancer

scientific article published on 09 August 2016

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

scientific article

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.

scientific article

The alpine violet, Viola biflora, is a rich source of cyclotides with potent cytotoxicity

scientific article

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

scientific article

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects

scientific article published on 28 October 2017

List of works by Joachim Gullbo

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

Aminopeptidase N (CD13) as a target for cancer chemotherapy

Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan ⬇️

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.

Evaluation of toxicity and antitumor activity of cycloviolacin O2 in mice

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

Novel activity of acriflavine against colorectal cancer tumor cells

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Preclinical activity of melflufen (J1) in ovarian cancer

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.

The alpine violet, Viola biflora, is a rich source of cyclotides with potent cytotoxicity

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects